Literature DB >> 20842989

Contraception choices in women with underlying medical conditions.

Rachel A Bonnema1, Megan C McNamara, Abby L Spencer.   

Abstract

Primary care physicians often prescribe contraceptives to women of reproductive age with comorbidities. Novel delivery systems (e.g., contraceptive patch, contraceptive ring, single-rod implantable device) may change traditional risk and benefit profiles in women with comorbidities. Effective contraceptive counseling requires an understanding of a woman's preferences and medical history, as well as the risks, benefits, adverse effects, and contraindications of each method. Noncontraceptive benefits of combined hormonal contraceptives, such as oral contraceptive pills, include regulated menses, decreased dysmenorrhea, and diminished premenstrual dysphoric disorder. Oral contraceptive pills may be used safely in women with a range of medical conditions, including well-controlled hypertension, uncomplicated diabetes mellitus, depression, and uncomplicated valvular heart disease. However, women older than 35 years who smoke should avoid oral contraceptive pills. Contraceptives containing estrogen, which can increase thrombotic risk, should be avoided in women with a history of venous thromboembolism, stroke, cardiovascular disease, or peripheral vascular disease. Progestin-only contraceptives are recommended for women with contraindications to estrogen. Depo-Provera, a long-acting injectable contraceptive, may be preferred in women with sickle cell disease because it reduces the frequency of painful crises. Because of the interaction between antiepileptics and oral contraceptive pills, Depo-Provera may also be considered in women with epilepsy. Implanon, the single-rod implantable contraceptive device, may reduce symptoms of dysmenorrhea. Mirena, the levonorgestrel-containing intrauterine contraceptive system, is an option for women with menorrhagia, endometriosis, or chronic pelvic pain.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20842989

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  8 in total

1.  Use of a modified reproductive life plan to improve awareness of preconception health in women with chronic disease.

Authors:  Pooja Mittal; Aparna Dandekar; Danielle Hessler
Journal:  Perm J       Date:  2014

2.  Mobile Technology for Improved Contraceptive Care in Morocco.

Authors:  Manal Kharbouch; Ali Idri; Taoufik Rachad; Hassan Alami; Leanne Redman; Youssef Stelate
Journal:  J Med Syst       Date:  2021-01-11       Impact factor: 4.460

Review 3.  Sex differences in stroke co-morbidities.

Authors:  Taylor E Branyan; Farida Sohrabji
Journal:  Exp Neurol       Date:  2020-06-23       Impact factor: 5.330

4.  Assessing safety in hormonal male contraception: a critical appraisal of adverse events reported in a male contraceptive trial.

Authors:  Carmen Abbe; Alison C Roxby
Journal:  BMJ Sex Reprod Health       Date:  2019-11-21

5.  Medical contraindications in women seeking combined hormonal contraception.

Authors:  Hanna Xu; David L Eisenberg; Tessa Madden; Gina M Secura; Jeffrey F Peipert
Journal:  Am J Obstet Gynecol       Date:  2013-11-16       Impact factor: 8.661

Review 6.  A Review of hormone-based therapies to treat adult acne vulgaris in women.

Authors:  M K Trivedi; K Shinkai; J E Murase
Journal:  Int J Womens Dermatol       Date:  2017-03-30

7.  Nexplanon Subdermal Implant: Assessment of Sexual Profile, Metabolism, and Bleeding in a Cohort of Italian Women.

Authors:  Maurizio Guida; Manuela Farris; Carmen Imma Aquino; Elena Rosato; Lucio M A Cipullo; Carlo Bastianelli
Journal:  Biomed Res Int       Date:  2019-01-31       Impact factor: 3.411

8.  Retrospective analysis of the impact of increasing access to long acting reversible contraceptives in a commercially insured population.

Authors:  Amy Law; Dominic Pilon; Richard Lynen; François Laliberté; Laurence Gozalo; Patrick Lefebvre; Mei Sheng Duh
Journal:  Reprod Health       Date:  2016-08-22       Impact factor: 3.223

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.